Maxi agreement in the American pharmaceutical sector. US giant Pfizer signed an agreement to acquire Global Blood Therapeutics, a California-based biopharmaceutical company. It is a'$5,4 billion deal, a figure including debt and net of cash acquired.
Going into detail, the boards of both companies unanimously approved the operation that Pfizer plans to finance with available liquidity. The company that together with its colleague BioNTech produced and distributed the anti-Covid vaccines worldwide will acquire all outstanding shares for $68,50 per share in cash.
What does Global Blood Therapeutics do
“The acquisition complements and enhances Pfizer's more than 30 years of experience in rare hematology and reinforces the company's commitment to thesickle cell anemia, bringing expertise, a portfolio and a leading pipeline,” the company said in a statement. For years Global Blood Therapeutics has been working onsickle cell anemia, which mainly affects people of African, Middle Eastern and South Asian origin. The company has developed tablets that target the root cause of the disease, which are approved by several countries and whose sales have been as high as $ 195 million in 2021. Pfizer plans to "accelerate the distribution of the treatment in the most affected parts of the world," the company said.
Stocks on the Stock Exchange
In the wake of the rumors relating to the possible agreement with Pfizer, Global Blood Therapeutics shares on the Nasdaq in the Thursday and Friday sessions they earned 88% of their value, rising to $63,84. At the opening today, the stock rose another 4,5% to $66,71. Instead, Pfizer shares rose by 0,3% to 49,38 dollars.
